| Literature DB >> 31754342 |
Bangzhu Chen1,2,3, Peng Gu1,2,3, Junshuang Jia1,4, Wei Liu2, Yumin Liu2, Wen Liu2, Tao Xu1,2,3, Xiaolin Lin1,4, Taoyan Lin1,4, Yu Liu1,2, Hengwei Chen1,2, Mingchen Xu2, Jin Yuan2, Jianing Zhang2, Yinghui Zhang5, Dong Xiao2,1,4, Weiwang Gu2,3,5,1.
Abstract
The Tibet minipig is a rare highland pig breed worldwide and has many applications in biomedical and agricultural research. However, Tibet minipigs are not like domesticated pigs in that their ovulation number is low, which is unfavourable for the collection of zygotes. Partly for this reason, few studies have reported the successful generation of genetically modified Tibet minipigs by zygote injection. To address this issue, we described an efficient way to generate gene-edited Tibet minipigs, the major elements of which include the utilization of synchronized oestrus instead of superovulation to obtain zygotes, optimization of the preparation strategy, and co-injection of clustered regularly interspaced short palindromic repeat sequences associated protein 9 (Cas9) mRNA and single-guide RNAs (sgRNAs) into the cytoplasm of zygotes. We successfully obtained allelic TYR gene knockout (TYR -/-) Tibet minipigs with a typical albino phenotype (i.e., red-coloured eyes with light pink-tinted irises and no pigmentation in the skin and hair) as well as TYR -/- IL2RG -/- and TYR -/- RAG1 -/- Tibet minipigs with typical phenotypes of albinism and immunodeficiency, which was characterized by thymic atrophy and abnormal immunocyte proportions. The overall gene editing efficiency was 75% for the TYR single gene knockout, while for TYR-IL2RG and TYR-RAG1 dual gene editing, the values were 25% and 75%, respectively. No detectable off-target mutations were observed. By intercrossing F0 generation minipigs, targeted genetic mutations can also be transmitted to gene-edited minipigs' offspring through germ line transmission. This study is a valuable exploration for the efficient generation of gene-edited Tibet minipigs with medical research value in the future. © The author(s).Entities:
Keywords: CRISPR/Cas9; Tibet minipig; cytoplasmic injection; gene editing; oestrus synchronization
Mesh:
Year: 2019 PMID: 31754342 PMCID: PMC6854383 DOI: 10.7150/ijbs.35930
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Comparison of oestrus synchronization and superovulation in Tibet minipigs
| Treatment | No. of treatment (head) | No. of oestrus (head) | Oestrus induction rate (%) | No. of operations (head) | No. of | Average No. of embryos (number/head) | Embryo quality | Sows can be reused to collect embryos | Need to observe oestrus every day | Require daily medication |
|---|---|---|---|---|---|---|---|---|---|---|
| 1ES | 30 | 27 | 90 | 14 | 89 | 6.36 | Good | Yes | No | Yes |
| 2S | 21 | 6 | 28.6 | 6 | 75 | 12.5 | Poor | No | Yes | No |
| 3ES+S | 5 | 1 | 20 | 1 | 20 | 20 | Poor | No | No | Yes |
Note: 1. ES, oestrus synchronization. The details are described in the previous section. 2. S, superovulation treatment. Superovulation was administered on the 14th to 15th day of the oestrus cycle. The sows' best oestrus state was set as day 0 of the oestrus cycle. The first day: intramuscular injection of PG (Prostaglandin) 500 mg at 10 a.m. and 4 p.m. respectively; the second day: intramuscular injection of PMSG (Pregnant Mare Serum Gonadotropin) 1500-750 IU at 10 a.m.; the fifth day: intramuscular injection of hCG (human Chorionic Gonadotropin) 500-750 IU at 4 p.m.; the sixth day: mating at 9 a.m. and 16 p.m.; and the seventh day: operation at 9-11 a.m. to collect embryos. 3. ES+S, oestrus synchronization combined with superovulation. Superovulation was performed on the 14th day of oestrous synchronization. For more details, refer to Zidek V, et al36.
Cytoplasmic microinjection of zygotes generates gene-edited pigs
| Surrogate | Microinjected embryo cell stage | CRISPR guide pairs | Gestation | No. of transferred embryos | No. of births | No. of births/ | Sex ratio of piglets | |||
|---|---|---|---|---|---|---|---|---|---|---|
| A | 1-cell stage | tyr-sg1/tyr-sg2 | 113 | 12 | 4 | 33.3% | 2:2 | 3 | / | / |
| B | 1-cell stage | tyr-sg1/tyr-sg2 | 113 | 9 | 4 | 44.4% | 1:3 | 4 | / | / |
| C | 2-cell stage | tyr-sg1/tyr-sg2/il2rg-sg1 | 114 | 11 | 4 | 36.4% | 3:1 | 2 | 1 (25%) | / |
| D | 2-cell stage | tyr-sg1/rag1-sg1/rag1-sg2 | 115 | 8 | 4 | 50% | 3:1 | 3 | / | 3 (75%) |
| Total | 114 ± 1 | 40 | 16 | 40% | 9:7 | 12 (75%) | / | / | ||
F0 generation piglets
| F0 generation piglet ID | Sex | Surrogate ID | Phenotypes | Genotypes |
|---|---|---|---|---|
| a1 | Male | A | Fully pigmented | Wild-type |
| a2 | Male | A | Albino | |
| a3 | Female | A | Albino | |
| a4 | Female | A | Albino | |
| b5 | Female | B | Albino | |
| b6 | Male | B | Albino | |
| b7 | Female | B | Albino | |
| b8 | Female | B | Albino | |
| c9 | Male | C | Albino, immunodeficiency | |
| c10 | Male | C | Fully pigmented | |
| c11 | Male | C | Partial pigment loss | |
| c12 | Female | C | Albino | |
| d13 | Male | D | Partial pigment loss, immunodeficiency | |
| d14 | Male | D | Albino, immunodeficiency | |
| d15 | Male | D | Albino, immunodeficiency | |
| d16 | Female | D | Albino |